Mehmet Sofuoglu, MD, PhD

• Ariadna Forray
• Charla Nich
• Elina A. Stefanovics
• Elise DeVito
• Haleh Nadim
• Ismene Petrakis
• Joao P. De Aquino
• Kimberly Yonkers
• Lorig Kachadourian
• MacKenzie Peltier
• Marek Chawarski
• R. Ross MacLean
• Ralitza Gueorguieva
• Robert Rosenheck
• Sarah Meshberg-Cohen
• Sarah Yip
• Suzanne Spinola
• Tore Eid
• Victor J. Avila-Quintero

Psychiatry; Psychotherapy; Tobacco; Substance-Related Disorders; Cocaine-Related Disorders; Psychiatry and Psychology

• Associations between Childhood Trauma and Tobacco Use Outcomes in Adults after Overnight Abstinence.Palmisano A, Schwartz E, Gueorguieva R, Sofuoglu M. Associations between Childhood Trauma and Tobacco Use Outcomes in Adults after Overnight Abstinence. Nicotine & Tobacco Research 2023 PMID: 37565294, DOI: 10.1093/ntr/ntad135.
• Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory studyDe Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.
• Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidenceOliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino J. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review Of Psychiatry 2023, ahead-of-print: 1-20. DOI: 10.1080/09540261.2023.2229430.
• Pharmacological Interventions for Impulsivity in Addictive DisordersSchwartz E, Palmisano A, Sofuoglu M. Pharmacological Interventions for Impulsivity in Addictive Disorders. Current Addiction Reports 2023, 10: 149-165. DOI: 10.1007/s40429-023-00486-3.
• Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary resultsMacLean R, Heapy A, Waters A, Wolkowicz N, Szollosy S, Meyerovich J, Sofuoglu M. Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. Drug And Alcohol Dependence 2023, 246: 109857. PMID: 37004461, PMCID: PMC10189744, DOI: 10.1016/j.drugalcdep.2023.109857.
• Opioid Use Disorder With Chronic Pain Increases Disease Burden and Service UseMacLean RR, Sofuoglu M, Stefanovics E, Rosenheck R. Opioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use. Psychological Services 2023, 20: 157-165. PMID: 34968125, PMCID: PMC9358616, DOI: 10.1037/ser0000607.
• Threshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-AdministrationMacLean RR, Eid T, Parida S, Gueorguieva R, DeVito EE, Sofuoglu M. Threshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-Administration. Experimental And Clinical Psychopharmacology 2023, 31: 37-45. PMID: 35254839, PMCID: PMC9448824, DOI: 10.1037/pha0000556.
• On the Edges: The Ethics of Human Studies with Psychedelic Substancesda Costa S, Sofuoglu M. On the Edges: The Ethics of Human Studies with Psychedelic Substances. 2023, 153-171. DOI: 10.1007/978-3-031-14339-7_9.
• Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion studySchwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.
• A Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSDPalmisano A, Meshberg-Cohen S, Petrakis I, Sofuoglu M. A Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSD. Psychological Trauma Theory Research Practice And Policy 2023 PMID: 36595460, DOI: 10.1037/tra0001410.
• Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studiesDe Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.
• Effect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanoloneNovick AM, Duffy KA, Johnson RL, Sammel MD, Cao W, Strasser AA, Sofuoglu M, Kuzma A, Loughead J, Morrow AL, Epperson CN. Effect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanolone. Biology Of Sex Differences 2022, 13: 60. PMID: 36274158, PMCID: PMC9590190, DOI: 10.1186/s13293-022-00472-w.
• Catechol-O-Methyltransferase Effects on Smoking: a Review and Proof of Concept of Sex-Sensitive EffectsDeVito E, Sofuoglu M. Catechol-O-Methyltransferase Effects on Smoking: a Review and Proof of Concept of Sex-Sensitive Effects. Current Behavioral Neuroscience Reports 2022, 9: 113-123. DOI: 10.1007/s40473-022-00251-2.
• Catechol-O-Methyltransferase Effects on Smoking: a Review and Proof of Concept of Sex-Sensitive EffectsDeVito E, Sofuoglu M. Catechol-O-Methyltransferase Effects on Smoking: a Review and Proof of Concept of Sex-Sensitive Effects. Current Behavioral Neuroscience Reports 2022, 9: 113-123. PMID: 36644316, PMCID: PMC9838826, DOI: 10.1007/s40473-022-00251-2.
• Pilot examination of stress, heart rate variability, and alcohol craving and use among female veteransHolzhauer CG, Epstein EE, Bickar L, Ellis RA, Pole N, Sofuoglu M, Smelson DA, Mattocks K. Pilot examination of stress, heart rate variability, and alcohol craving and use among female veterans. Frontiers In Psychiatry 2022, 13: 886801. PMID: 36159929, PMCID: PMC9500469, DOI: 10.3389/fpsyt.2022.886801.
• Cocaine Use Disorder (CUD): Current Clinical PerspectivesSchwartz EKC, Wolkowicz NR, De Aquino JP, MacLean RR, Sofuoglu M. Cocaine Use Disorder (CUD): Current Clinical Perspectives. Substance Abuse And Rehabilitation 2022, 13: 25-46. PMID: 36093428, PMCID: PMC9451050, DOI: 10.2147/sar.s337338.
• Progesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence.Novick AM, Duffy KA, Johnson RL, Sammel MD, Cao W, Strasser AA, Sofuoglu M, Kuzma A, Loughead J, Epperson CN. Progesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence. Nicotine & Tobacco Research 2022, 24: 1898-1905. PMID: 35713950, PMCID: PMC9653080, DOI: 10.1093/ntr/ntac146.
• Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humansDe Aquino JP, DeVito EE, Xie C, Meyerovich J, Parida S, Gueorguieva R, Sofuoglu M. Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology 2022, 239: 2809-2818. PMID: 35554617, DOI: 10.1007/s00213-022-06162-0.
• P687. Sex-Dependent Effects of Progesterone on Nicotine Withdrawal and Neural Response to Smoking Cues During Brief AbstinenceNovick A, Duffy K, Johnson R, Sammel M, Cao W, Strasser A, Sofuoglu M, Kuzma A, Loughead J, Epperson C. P687. Sex-Dependent Effects of Progesterone on Nicotine Withdrawal and Neural Response to Smoking Cues During Brief Abstinence. Biological Psychiatry 2022, 91: s368-s369. DOI: 10.1016/j.biopsych.2022.02.924.
• Plasma Menthol Glucuronide as a Biomarker for the Behavioral Effects of Menthol and Nicotine in HumansGueorguieva R, Schwartz EKC, MacLean RR, DeVito EE, Eid T, Wu R, O’Malley S, Sofuoglu M. Plasma Menthol Glucuronide as a Biomarker for the Behavioral Effects of Menthol and Nicotine in Humans. Frontiers In Pharmacology 2022, 13: 844824. PMID: 35431934, PMCID: PMC9009207, DOI: 10.3389/fphar.2022.844824.
• Modafinil does not reduce cocaine use in methadone-maintained individualsDeVito EE, Poling J, Babuscio T, Nich C, Carroll KM, Sofuoglu M. Modafinil does not reduce cocaine use in methadone-maintained individuals. Drug And Alcohol Dependence Reports 2022, 2: 100032. PMID: 36310662, PMCID: PMC9615926, DOI: 10.1016/j.dadr.2022.100032.
• Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory scienceDe Aquino JP, MacLean RR, Gueorguieva R, DeVito EE, Eid T, Sofuoglu M. Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology 2022, 27: e13161. PMID: 35229960, PMCID: PMC8903077, DOI: 10.1111/adb.13161.
• Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studiesDe Aquino JP, Parida S, Avila-Quintero VJ, Flores J, Compton P, Hickey T, Gómez O, Sofuoglu M. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug And Alcohol Dependence 2021, 228: 109097. PMID: 34601272, PMCID: PMC8595687, DOI: 10.1016/j.drugalcdep.2021.109097.
• The Pharmacology of Buprenorphine Microinduction for Opioid Use DisorderDe Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.
• Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokersMacLean RR, DeVito EE, Eid T, Parida S, Gueorguieva R, Sofuoglu M. Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology 2021, 238: 2083-2090. PMID: 33796907, PMCID: PMC8715498, DOI: 10.1007/s00213-021-05833-8.
• The Impact of Chronic Pain on Opioid Use Disorder Treatment OutcomesMacLean R, Spinola S, Garcia-Vassallo G, Sofuoglu M. The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes. Current Addiction Reports 2021, 8: 100-108. DOI: 10.1007/s40429-020-00352-6.
• Catechol-O-Methyltransferase Activity Impacts Smoking Urges and Withdrawal in WomenDeVito E, Herman A, Sofuoglu M. Catechol-O-Methyltransferase Activity Impacts Smoking Urges and Withdrawal in Women. Biological Psychiatry 2020, 87: s149. DOI: 10.1016/j.biopsych.2020.02.395.
• Chapter 23 Pharmacological cognitive enhancersPeltier M, Sofuoglu M. Chapter 23 Pharmacological cognitive enhancers. 2020, 303-320. DOI: 10.1016/b978-0-12-815298-0.00023-x.
• Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorderDeVito EE, Carroll KM, Babuscio T, Nich C, Sofuoglu M. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal Of Substance Abuse Treatment 2019, 107: 29-37. PMID: 31757262, PMCID: PMC6918721, DOI: 10.1016/j.jsat.2019.08.009.
• Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid UseCarroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.
• Pharmacotherapies for PTSD and Substance Use DisordersKachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.
• The Opioid Crisis: Filling in the PictureYonkers KA, Sofuoglu M. The Opioid Crisis: Filling in the Picture. Psychiatric Research And Clinical Practice 2019, 1: 2-3. PMID: 36101565, PMCID: PMC9175864, DOI: 10.1176/appi.prcp.20180014.
• Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patientsArout CA, Waters AJ, MacLean RR, Compton P, Sofuoglu M. Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology 2018, 236: 2857-2866. PMID: 30564869, PMCID: PMC6581631, DOI: 10.1007/s00213-018-5146-7.
• Pharmacological and Behavioral Treatment of Opioid Use DisorderSofuoglu M, DeVito E, Carroll K. Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research And Clinical Practice 2018, 1: 4-15. PMCID: PMC9175946, DOI: 10.1176/appi.prcp.20180006.
• The Cholinergic System as a Treatment Target for Opioid Use DisorderJensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.
• Stimulants and Mood DisordersMacLean R, Sofuoglu M. Stimulants and Mood Disorders. Current Addiction Reports 2018, 5: 323-329. DOI: 10.1007/s40429-018-0212-0.
• Rates and correlates of specialized pain clinic use nationally in the veterans health administrationArout C, Sofuoglu M, Rosenheck R. Rates and correlates of specialized pain clinic use nationally in the veterans health administration. Drug And Alcohol Dependence 2017, 171: e10-e11. DOI: 10.1016/j.drugalcdep.2016.08.044.
• Neurocognitive Function as a Treatment Target for Tobacco Use DisorderRobinson C, Waters A, Kang N, Sofuoglu M. Neurocognitive Function as a Treatment Target for Tobacco Use Disorder. Current Behavioral Neuroscience Reports 2017, 4: 10-20. DOI: 10.1007/s40473-017-0105-x.
• Inhalation of Alcohol Vapor: Measurement and ImplicationsMacLean RR, Valentine GW, Jatlow PI, Sofuoglu M. Inhalation of Alcohol Vapor: Measurement and Implications. Alcoholism Clinical And Experimental Research 2017, 41: 238-250. PMID: 28054395, PMCID: PMC6143144, DOI: 10.1111/acer.13291.
• Receptivity to a peer counselling program and recovery atmosphere as perceived by Veterans Health Administration peer support specialists and supervisorsStefanovics E, Drebing C, Sweeney P, Sofuoglu M, Rosenheck R. Receptivity to a peer counselling program and recovery atmosphere as perceived by Veterans Health Administration peer support specialists and supervisors. American Journal Of Psychiatric Rehabilitation 2017, 20: 62-73. DOI: 10.1080/15487768.2016.1267050.
• Intravenous Nicotine Self-Administration in Smokers: Dose–Response Function and Sex DifferencesJensen KP, DeVito EE, Valentine G, Gueorguieva R, Sofuoglu M. Intravenous Nicotine Self-Administration in Smokers: Dose–Response Function and Sex Differences. Neuropsychopharmacology 2015, 41: 2034-2040. PMID: 26717881, PMCID: PMC4908640, DOI: 10.1038/npp.2015.373.
• The effects of alcohol-containing e-cigarettes on young adult smokersValentine GW, Jatlow PI, Coffman M, Nadim H, Gueorguieva R, Sofuoglu M. The effects of alcohol-containing e-cigarettes on young adult smokers. Drug And Alcohol Dependence 2015, 159: 272-276. PMID: 26778759, PMCID: PMC5171208, DOI: 10.1016/j.drugalcdep.2015.12.011.
• VA Patients With High Numbers of Opioid PrescriptionsPetrakis I, Sofuoglu M, Rosenheck R. VA Patients With High Numbers of Opioid Prescriptions. Addictive Disorders & Their Treatment 2015, 14: 167-175. DOI: 10.1097/adt.0000000000000058.
• Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorderSchottenfeld R, Chawarski M, Sofuoglu M, Chooi W, Zaharim N, Yasin M, Ahmad I, Jaapar S, Kasinather V. Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorder. Drug And Alcohol Dependence 2015, 156: e200. DOI: 10.1016/j.drugalcdep.2015.07.538.
• Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological ConsiderationsArout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations. CNS Drugs 2015, 29: 465-486. PMID: 26142224, DOI: 10.1007/s40263-015-0255-x.
• COMT Val/Met genotype associations with treatment response from a randomized clinical trial of CBT4CBTCarroll K, Herman A, DeVito E, Frankforter T, Sofuoglu M. COMT Val/Met genotype associations with treatment response from a randomized clinical trial of CBT4CBT. Drug And Alcohol Dependence 2015, 146: e240. DOI: 10.1016/j.drugalcdep.2014.09.120.
• Carvedilol treatment reduces cocaine use in methadone-maintained cocaine usersSofuoglu M, Babuscio T, Carroll K. Carvedilol treatment reduces cocaine use in methadone-maintained cocaine users. Drug And Alcohol Dependence 2015, 146: e103. DOI: 10.1016/j.drugalcdep.2014.09.647.
• Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot studyYonkers KA, Forray A, Nich C, Carroll KM, Hine C, Merry BC, Shaw H, Shaw J, Sofuoglu M. Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. The Lancet Psychiatry 2014, 1: 360-367. PMID: 25328863, PMCID: PMC4199242, DOI: 10.1016/s2215-0366(14)70333-5.
• Stimulant-Related DisordersSofuoglu M, Forray A. Stimulant-Related Disorders. 2014 DOI: 10.1176/appi.books.9781585625048.gg54.
• Chapter Twelve Cognitive Effects of NicotineSofuoglu M, Herman A, Robinson C, Waters A. Chapter Twelve Cognitive Effects of Nicotine. 2014, 367-385. DOI: 10.1016/b978-0-12-418679-8.00012-5.
• Chapter 35 Medications to Treat Addictions Nicotine ReplacementHerman A, Sofuoglu M. Chapter 35 Medications to Treat Addictions Nicotine Replacement. 2013, 337-343. DOI: 10.1016/b978-0-12-398338-1.00035-x.
• Rapid Nicotine Clearance is Associated with Greater Reward and Heart Rate Increases from Intravenous NicotineSofuoglu M, Herman AI, Nadim H, Jatlow P. Rapid Nicotine Clearance is Associated with Greater Reward and Heart Rate Increases from Intravenous Nicotine. Neuropsychopharmacology 2012, 37: 1509-1516. PMID: 22334123, PMCID: PMC3327855, DOI: 10.1038/npp.2011.336.
• Reply: Response to Letter to the EditorSofuoglu M, Yoo S, Hill K, Mooney M. Reply: Response to Letter to the Editor. Neuropsychopharmacology 2008, 33: 2044-2044. DOI: 10.1038/sj.npp.1301546.
• Treatment of stimulant dependenceSofuoglu M, Agath K, Kosten T. Treatment of stimulant dependence. 2008, 369-380. DOI: 10.1017/cbo9780511544392.021.
• GABAergic Agents for the Treatment of Nicotine DependenceSofuoglu M, Lappalainen J. GABAergic Agents for the Treatment of Nicotine Dependence. 2006, 177-186. DOI: 10.1201/9781420005431.ch12.
• Depressive symptoms modulate the subjective and physiological response to cocaine in humansSofuoglu M, Brown S, Babb D, Hatsukami D. Depressive symptoms modulate the subjective and physiological response to cocaine in humans. Drug And Alcohol Dependence 2001, 63: 131-137. PMID: 11376917, DOI: 10.1016/s0376-8716(00)00199-x.
• Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in womenSofuoglu M, Babb D, Hatsukami D. Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in women. Pharmacology Biochemistry And Behavior 2001, 69: 299-304. PMID: 11420098, DOI: 10.1016/s0091-3057(01)00527-5.
• Intravenous cocaine increases plasma epinephrine and norepinephrine in humansSofuoglu M, Nelson D, Babb D, Hatsukami D. Intravenous cocaine increases plasma epinephrine and norepinephrine in humans. Pharmacology Biochemistry And Behavior 2001, 68: 455-459. PMID: 11325399, DOI: 10.1016/s0091-3057(01)00482-8.
• Characteristics of research volunteers for inpatient cocaine studies Focus on selection biasSofuoglu M, Dudish-Poulsen S, Nicodemus K, Babb D, Hatsukami D. Characteristics of research volunteers for inpatient cocaine studies Focus on selection bias. Addictive Behaviors 2000, 25: 785-790. PMID: 11023020, DOI: 10.1016/s0306-4603(00)00064-2.
• Carvedilol affects the physiological and behavioral response to smoked cocaine in humansSofuoglu M, Brown S, Babb D, Pentel P, Hatsukami D. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug And Alcohol Dependence 2000, 60: 69-76. PMID: 10821991, DOI: 10.1016/s0376-8716(00)80009-5.
• Effects of Labetalol Treatment on the Physiological and Subjective Response to Smoked CocaineSofuoglu M, Brown S, Babb D, Pentel P, Hatsukami D. Effects of Labetalol Treatment on the Physiological and Subjective Response to Smoked Cocaine. Pharmacology Biochemistry And Behavior 2000, 65: 255-259. PMID: 10672977, DOI: 10.1016/s0091-3057(99)00201-4.
• Individual Differences in the Subjective Response to Smoked Cocaine in HumansSofuoglu M, Brown S, Dudish-Poulsen S, Hatsukami D. Individual Differences in the Subjective Response to Smoked Cocaine in Humans. The American Journal Of Drug And Alcohol Abuse 2000, 26: 591-602. PMID: 11097194, DOI: 10.1081/ada-100101897.
• Predictors of cardiovascular response to smoked cocaine in humansSofuoglu M, Nelson D, Dudish-Poulsen S, Lexau B, Pentel P, Hatsukami D. Predictors of cardiovascular response to smoked cocaine in humans. Drug And Alcohol Dependence 2000, 57: 239-245. PMID: 10661674, DOI: 10.1016/s0376-8716(99)00055-1.
• Sex and Menstrual Cycle Differences in the Subjective Effects From Smoked Cocaine in HumansSofuoglu M, Dudish-Poulsen S, Nelson D, Pentel P, Hatsukami D. Sex and Menstrual Cycle Differences in the Subjective Effects From Smoked Cocaine in Humans. Experimental And Clinical Psychopharmacology 1999, 7: 274-283. PMID: 10472516, DOI: 10.1037/1064-1297.7.3.274.
• Effects of phenytoin on cocaine self-administration in humans1Portions of this report were presented at the 59th Annual Scientific Meeting of the College on the Problems of Drug Dependence, Nashville, June 1997.1Sofuoglu M, Pentel P, Bliss R, Goldman A, Hatsukami D. Effects of phenytoin on cocaine self-administration in humans1Portions of this report were presented at the 59th Annual Scientific Meeting of the College on the Problems of Drug Dependence, Nashville, June 1997.1. Drug And Alcohol Dependence 1999, 53: 273-275. PMID: 10080053, DOI: 10.1016/s0376-8716(98)00140-9.
• Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugsDeBattista C, Sofuoglu M, Schatzberg A. Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. Biological Psychiatry 1998, 44: 341-347. PMID: 9755356, DOI: 10.1016/s0006-3223(98)00161-9.
• Effects of cotinine on cigarette self-administrationHatsukami D, Lexau B, Nelson D, Pentel P, Sofuoglu M, Goldman A. Effects of cotinine on cigarette self-administration. Psychopharmacology 1998, 138: 184-189. PMID: 9718288, DOI: 10.1007/s002130050661.
• Development of obsessive symptoms during nefazodone treatmentSofuoglu M, Debattista C. Development of obsessive symptoms during nefazodone treatment. American Journal Of Psychiatry 1996, 153: 577b-578. PMID: 8599413, DOI: 10.1176/ajp.153.4.577b.
• 7-Benzylidenenaltrexone (BNTX): A selective δ1 opioid receptor antagonist in the mouse spinal cordSofuoglu M, Portoghese P, Takemori A. 7-Benzylidenenaltrexone (BNTX): A selective δ1 opioid receptor antagonist in the mouse spinal cord. Life Sciences 1993, 52: 769-775. PMID: 8383271, DOI: 10.1016/0024-3205(93)90240-4.
• δ-Opioid receptor binding in mouse brain: Evidence for heterogeneous binding sitesSofuoglu M, Portoghese P, Takemori A. δ-Opioid receptor binding in mouse brain: Evidence for heterogeneous binding sites. European Journal Of Pharmacology 1992, 216: 273-277. PMID: 1327813, DOI: 10.1016/0014-2999(92)90370-j.
• Maintenance of acute morphine tolerance in mice by selective blockage of κ opioid receptors with norbinaltorphimineSofuoglu M, Portoghese P, Takemori A. Maintenance of acute morphine tolerance in mice by selective blockage of κ opioid receptors with norbinaltorphimine. European Journal Of Pharmacology 1992, 210: 159-162. PMID: 1318206, DOI: 10.1016/0014-2999(92)90666-r.
• Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes.Sofuoglu M, Portoghese P, Takemori A. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. Journal Of Pharmacology And Experimental Therapeutics 1991, 257: 676-80. PMID: 1851833.
• Cross-tolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypesSofuoglu M, Portoghese P, Takemori A. Cross-tolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypes. Life Sciences 1991, 49: pl153-pl156. PMID: 1658509, DOI: 10.1016/0024-3205(91)90397-t.
• Naloxone produces protracted tolerance in mice treated with a single dose of morphine.Sofuoglu M, Takemori A. Naloxone produces protracted tolerance in mice treated with a single dose of morphine. Journal Of Pharmacology And Experimental Therapeutics 1990, 254: 836-40. PMID: 2395115.
• Maintenance of morphine dependence by naloxone in acutely dependent mice.Sofuoglu M, Sato J, Takemori A. Maintenance of morphine dependence by naloxone in acutely dependent mice. Journal Of Pharmacology And Experimental Therapeutics 1990, 254: 841-6. PMID: 2395116.
• Differential antagonism of DSLET and DPDPE by novel delta opioid receptor antagonistsSofuoglu M, Portoghese P, Takemori A. Differential antagonism of DSLET and DPDPE by novel delta opioid receptor antagonists. European Journal Of Pharmacology 1990, 183: 2322. DOI: 10.1016/0014-2999(90)93879-u.